- The findings of a new study in mice may help develop new medications to treat high blood pressure.
- Researchers studied mice without a protein called FXR1, which is related to the protein implicated in Fragile X syndrome; the mice without FXR1 had lower diastolic blood pressure compared to mice with the protein.
- The findings suggest two mechanisms through which FXR1 may regulate blood pressure and vascular contractility: mRNA stability and functional activity by protein-protein interactions.
Embargoed for release at 11:00 a.m. PT/2:00 p.m. ET Thursday, May 12, 2022
SEATTLE, May 12, 2022 — A new study in mice has identified FXR1, a protein in the same family as the one implicated in Fragile X syndrome, as a potential target for creating a new type of blood pressure-lowering medicine, according to preliminary research presented at the American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2022. The meeting is being held May 12-14, 2022, in Seattle and is a premier global exchange of the latest advances in new and emerging scientific research in arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery and functional genomics.
Fragile X syndrome, or FXS, is the most common known cause of inherited intellectual disability caused by mutations on the X chromosome. The CDC estimates FXS affects 1 in 7,000 males and 1 in 11,000 females born each year in the U.S. FXS may lead to developmental delays, learning disabilities and behavioral problems, with symptoms being more severe among boys compared to girls.
FXS is caused by mutations to the gene FMR1, which codes for an RNA-binding protein FMRP that is believed to play a role in the development of connections between nerve cells in the brain.
FXR1 belongs to the same family of RNA-binding proteins as FMRP and is muscle-specific. RNA-binding proteins help turn genes on and off and are essential to numerous cellular processes.
“In my previous research on FXR1, I expected to see more transcription factors, translation factors, factors that regulate mRNA interact with FXR1,” said Amanda St. Paul, lead study author and a Ph.D. candidate at the Lewis Katz School of Medicine at Temple University in Philadelphia. “It was really surprising to find that FXR1 binds to a lot of actin-binding proteins and other proteins involved in the cytoskeleton.” Transcription and translation factors are proteins that help turn certain genes on and off. Actin proteins are responsible for the contraction and relaxation of muscles.
St. Paul and colleagues developed a mouse model where FXR1 can be deleted in smooth muscle cells – the same kind that make up blood vessels in humans. The mice were genetically modified so that the FXR1 gene could be deleted by administering the medication tamoxifen.
With the FXR1 gene deleted, the researchers noted that the vascular smooth muscle cells behaved differently compared to those of the mice with active FXR1.
“We found that vascular smooth muscle cells without FXR1 don't proliferate, they don't adhere, they don't migrate, which are activities dependent on a properly functioning cytoskeleton. And these are all what a vascular smooth muscle cell should be doing,” St. Paul said.
Knocking out FXR1 had another consequence that was eye-opening: “When you take away FXR1 from the smooth muscle in these mice, they also had decreased diastolic blood pressure compared to control mice,” St. Paul said.
The analysis found that:
- Depleting FXR1 decreased the ability of blood vessel cells to contract; and
- When FXR1 is deleted, the mice had decreased diastolic blood pressure compared to control mice. This was measured using telemetry, an in-vivo measure of blood pressure.
According to St. Paul, these findings suggest that targeting FXR1 in the vascular smooth muscle cells, or the contractile pathway it regulates, may be a promising avenue for the development of anti-hypertensive medications. “A lot of medication targets don’t focus on the cytoskeleton. Since FXR1 is muscle-specific, it gives us a specific target and pathway to examine further,” she said. “Millions of people have high blood pressure; finding new ways to improve blood pressure is important.”
Future work for St. Paul and colleagues will involve investigating whether FXR1’s activity in smooth muscle cells is dependent on its ability to interact with cytoskeletal proteins and if deleting FXR1 is effective in reducing blood pressure in a hypertensive mouse model.
St. Paul was recognized with the American Heart Association’s ATVB Diversity Outreach Travel Grant for Young Investigators in April. The purpose of this award, conferred by the Council on Arteriosclerosis, Thrombosis and Vascular Biology, is to encourage minority early career investigators and students to participate in the Vascular Discovery: From Genes to Medicine Scientific Sessions.
Nearly half of all adults in the U.S., defined by the 2017 American Heart Association/American College of Cardiology high blood pressure guidelines as systolic (top number) blood pressure equal to or greater than 130 mm Hg or a diastolic (bottom number) blood pressure equal to or greater than 80 mm Hg, and nearly. High blood pressure is a major risk factor for cardiovascular disease and stroke and increases the risks of kidney disease, visual loss and more. In 2019, more than half a million people who died in the U.S. had high blood pressure as a primary or contributing cause of death.
Co-authors are Kyle Preston, Ph.D.; Cali Corbett, B.S.; Tani Leigh, B.A.; Sheri E. Kelemen; Satoru Eguchi, M.D., Ph.D.; Michael Autieri, Ph.D. Authors’ disclosures are listed in the abstract.
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. Abstracts presented at the Association’s scientific meetings are not peer-reviewed, rather, they are curated by independent review panels and are considered based on the potential to add to the diversity of scientific issues and views discussed at the meeting. The findings are considered preliminary until published as a full manuscript in a peer-reviewed scientific journal.
The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
- Multimedia is available on the right column of the news release link: https://newsroom.heart.org/news/protein-related-to-fragile-x-syndrome-may-be-a-new-target-for-blood-pressure-medicines?preview=6a5485c728aef32838f2e478e813f70d
- AHA news release: Gene map may identify heart disease risk for people with Type 2 diabetes (April 2022)
- AHA health information: The Facts About High Blood Pressure
- AHA National Hypertension Control Initiative
- AHA health information: Stress and heart health
- Follow AHA/ASA news from the meeting on Twitter @HeartNews, #VascularDiscovery22
The American Heart Association’s Vascular Discovery: From Genes to Medicine Scientific Sessions 2022 is the world’s premier meeting dedicated to the latest advances in new and emerging scientific research in the areas of arteriosclerosis, thrombosis, vascular biology, genomics, precision medicine, peripheral vascular disease and vascular surgery. The meeting will be held May 12-14, 2022 in Seattle. The Vascular Discovery 2022 Scientific Sessions program is planned by the American Heart Association’s Council on Arteriosclerosis, Thrombosis and Vascular Biology and the Peripheral Vascular Disease Council, in cooperation with the Council on Genomic and Precision Medicine and the Society for Vascular Surgery, The meeting is of special interest to scientists and clinicians in cardiovascular medicine, cardiovascular research, thrombosis research, clinical cardiology, molecular/cellular biology, vascular biology, vascular medicine, vascular surgery, endocrinology, genetics, functional genomics, hematology, immunology and physiology. Follow the conference on Twitter at #VascularDiscovery22.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA Communications & Media Relations in Dallas: 214-706-1173; email@example.com
Maggie Francis: 214-706-1382 Maggie.Francis@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)